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1	Introduction









































with	 the	 possibility	 of	 having	 aberrant	 angiogenesis	 at	 higher	 concentrations	 (Banfi	et	al.,	2005).	 Another	 important	 aspect	 is	 the	 duration	 of	 the	VEGF	 treatment,	 although	 exposure	 time	 can	 be	 extended	 for	weeks	 to	 achieve
angiogenic	effect	(Amsden	et	al.,	2010;	Bhardwaj	et	al.,	2008;	Cleland	et	al.,	2001),	a	few	days	of	localised	VEGF	treatment	can	be	enough	to	elicit	angiogenic	effect	and	wound	healing	(Chereddy	et	al.,	2015).
The	aim	of	this	study	is	to	provide	an	engineered	formulation	from	PLGA	microspheres	to	deliver	a	therapeutic	dose	of	VEGF	in	the	right	place	and	for	an	appropriate	length	of	time	to	induce	angiogenesis.	PLGA	has	a	long



















UK)	 to	 form	 the	primary	water-in-oil	 emulsion.	The	 latter	was	 then	homogenised	 in	350 ml	of	0.3%	polyvinyl	alcohol	at	2100 rpm,	 the	 resultant	water-in-oil-in-water	double	emulsion	was	 left	 stirring	 for	 four	hours	 to	 allow	DCM





















encapsulated	within	microspheres	were	performed	 in	aqueous	buffers	over	3 weeks.	Aliquots	 (25 mg)	of	 the	microspheres	 (triplicate	samples	 from	each	batch)	were	suspended	 in	1 ml	phosphate	buffered	saline	 (PBS,	pH	7.4)	and
samples	were	 left	 on	 a	3-dimensional	 shaker	 (Gyrotwister,	Fisher	Scientific	UK	Ltd)	 at	 10 rpm	 in	 a	humidified	 incubator	 at	 37 °C.	Samples	were	 taken	 every	 day	 in	 the	 first	week	 then	 continued	 every	 two	days	where	 1 ml	PBS




































































The	 formulation	was	 designed	 to	 produce	 injectable	microspheres	 (∼80-µm	diameter)	 through	 a	 hypodermic	 needle	 (Qutachi	 et	 al.,	 2014).	 This	 delivery	method	 is	 a	minimally	 invasive	 technique	 for	 clinical	 applications






tumour.	Therefore	 for	 therapeutic	angiogenesis,	 the	minimum	 fluctuation	 in	VEGF	release	associated	with	zero	order	 release	kinetics	 for	 the	 required	duration	may	be	more	appropriate	 than	 the	conventional	bi/triphasic	 release
pattern	from	other	PLGA	based	formulations	(Bhardwaj	et	al.,	2008).
The	 release	mechanism	 through	 PLGA	 polymer	 reflects	 a	 complex	 interplay	 between	 drug	 diffusion	 through	 the	matrix,	 polymer	 degradation	 and	 swelling	 (Sandor	 et	 al.,	 2001).	 The	 transient	 initial	 burst	 phase	 of	 the
encapsulated	molecules	can	be	attributed	to	the	diffusion	of	surface	molecules	within	the	polymer	matrix	(Langer,	1990).	This	is	followed	by	a	sharp	decline,	which	continues	depending	on	the	polymer	characteristics	until	the	polymer
matrix	become	soft	due	to	polymer	degradation	(Park,	1995).	The	conventional	PLGA	microspheres,	might	not	be	the	best	option	for	growth	factors	delivery	due	to	the	risk	the	increased	core	acidity	rooted	to	the	degradation	by-
products	which	could	be	responsible	for	compromising	the	bioactivity	(Hines	and	Kaplan,	2013)	and	inducing	an	auto-catalytic	degradation	of	the	polymer	matrix	(Sandor	et	al.,	2001).	However,	VEGF	is	an	acid	stable	growth	factor
with	enhanced	bioactivity	at	acidic	pH	(Goerges	and	Nugent,	2004).	Furthermore,	PLGA-PEG-PLGA	triblock	copolymer	is	also	an	FDA	approved	polymer	(Chen	et	al.,	2017)	which	works	as	a	release	modifier	by	providing	hydrophilic
micro-channels	with	the	hydrophobic	polymer	matrix	to	facilitate	the	growth	factor	release	by	diffusion	and	minimise	the	accumulation	of	acidic	by	products	(Qodratnama	et	al.,	2015).	This	enhances	steady	state	release	and	appears	to
achieve	a	constant	zero	order	release	with	PLGA	85:15.
Difficulty	in	preserving	growth	factor’s	biological	activity	is	another	challenge	for	therapeutic	application.	Although	the	PLGA	matrix	provides	a	physical	protection	for	sensitive	molecules	following	injection	into	the	body,	the
payload	still	has	to	go	through	a	harsh	environment	during	microspheres	fabrication.	The	use	of	a	carrier	protein	such	as	HSA	provides	a	reliable	protection	for	the	bioactive	molecules	to	preserve	biological	activity.	Denaturation	of
growth	factors	is	expected	to	commence	at	the	interphase	between	aqueous	and	organic	solvent	during	emulsion	formation.	This	is	probably	due	to	partial	solvation	and	hence	changing	in	the	structural	confirmation	of	the	growth
factor	molecule.	The	presence	of	HSA	at	high	concentration	at	the	interphase	will	work	as	shielding	agent	at	the	interphase	and	preserve	the	growth	factor’s	biological	activity	(van	de	Weert	et	al.,	2000).
Vascularisation	is	under	tight	regulated	control	in	the	body	which	is	essential	to	prevent	hypoxia/nutrient	starvation/waste	build	up	after	tissue	damage.	The	use	of	VEGF	initially	showed	promise	as	a	therapy	but	it’s	use	and
effects	can	vary	in	the	body	with	low	or	hyper-physiological	dose	of	VEGF	leading	to	ineffective	or	malformed	leaky	vessels	as	in	haemangioma	formation	(Ozawa	et	al.,	2004).	Physiological	angiogenesis	can	be	achieved	at	20 ng/mL
which	appears	to	be	plateaued	at	50 ng/mL	(Yue	and	Tomanek,	2001).	The	PLGA	formulation	in	this	research	maintained	a	constant	release	of	VEGF	between	10	and	20 ng/mL	for	seven	days,	which	proved	to	be	effective	in	inducing
angiogenesis	in	an	in	ovo	CAM	model.
5	Conclusion
In	summary,	the	work	in	this	research	provides	a	formulation	with	engineered	release	kinetics	to	achieve	effective	VEGF	delivery	to	enhance	angiogenesis.	The	present	formulation	has	potential	as	a	treatment	for	ischemic
wound	diseases.	The	main	advantage	here	is	sustained	VEGF	delivery	at	therapeutic	concentration	with	minimum	variability	over	the	treatment	period.	The	polymer	matrix	has	been	designed	to	degrade	gradually	into	metabolites,
which	are	readily	cleared	by	the	body.
Declaration	of	interests
None.
Acknowledgement
Authors	would	gratefully	acknowledge	regenerative	medicine	platform	hub	“acellular	approaches	for	therapeutic	delivery”	(MR/K026682/1)	for	support.
References
Amsden	B.G.,	Timbart	L.,	Marecak	D.,	Chapanian	R.,	Tse	M.Y.	and	Pang	S.C.,	VEGF-induced	angiogenesis	following	localized	delivery	via	injectable,	low	viscosity	poly(trimethylene	carbonate),	J.	Control.	Release	145,	2010,
109–115.
Banfi	A.,	von	Degenfeld	G.	and	Blau	H.M.,	Critical	role	of	microenvironmental	factors	in	angiogenesis,	Curr.	Atheroscler.	Rep.	7,	2005,	227–234.
Bhardwaj	U.,	Papadimitrakopoulos	F.	and	Burgess	D.J.,	A	review	of	the	development	of	a	vehicle	for	localized	and	controlled	drug	delivery	for	implantable	biosensors,	J.	Diabetes	Sci.	Technol.	2,	2008,	1016–1029.
Blau	H.M.	and	Banfi	A.,	The	well-tempered	vessel,	Nat.	Med.	7,	2001,	532–534.
Cartland	S.P.,	Genner	S.W.,	Zahoor	A.	and	Kavurma	M.M.,	Comparative	evaluation	of	TRAIL,	FGF-2	and	VEGF-A-induced	angiogenesis	in	vitro	and	in	vivo,	Int.	J.	Mol.	Sci.	17,	2016.
Chen	J.R.,	Yang	L.,	Guo	L.	and	Duan	X.J.,	Sodium	hyaluronate	as	a	drug-release	system	for	VEGF	165	improves	graft	revascularization	in	anterior	cruciate	ligament	reconstruction	in	a	rabbit	model,	Exp.	Ther.	Med.	4,	2012
430–434.
Chen	X.,	Chen	J.,	Li	B.,	Yang	X.,	Zeng	R.,	Liu	Y.,	Li	T.,	Ho	R.J.Y.	and	Shao	J.,	PLGA-PEG-PLGA	triblock	copolymeric	micelles	as	oral	drug	delivery	system:	In	vitro	drug	release	and	in	vivo	pharmacokinetics	assessment,	J.
Colloid	Interface	Sci.	490,	2017,	542–552.
Chereddy	K.K.,	Lopes	A.,	Koussoroplis	S.,	Payen	V.,	Moia	C.,	Zhu	H.,	Sonveaux	P.,	Carmeliet	P.,	des,	Rieux,	A,,	Vandermeulen,	G,	and,	Preat	and	V,,	Combined	effects	of	PLGA	and	vascular	endothelial	growth	factor	promote	the
healing	of	non-diabetic	and	diabetic	wounds,	Nanomedicine	11,	2015,	1975–1984.
Cleland	J.L.,	Duenas	E.T.,	Park	A.,	Daugherty	A.,	Kahn	J.,	Kowalski	J.	and	Cuthbertson	A.,	Development	of	poly-(D,	L-lactide–coglycolide)	microsphere	formulations	containing	recombinant	human	vascular	endothelial	growth
factor	to	promote	local	angiogenesis,	J.	Control.	Release	72,	2001,	13–24.
des	Rieux	A.,	Ucakar	B.,	Mupendwa	B.P.,	Colau	D.,	Feron	O.,	Carmeliet	P.	and	Preat	V.,	3D	systems	delivering	VEGF	to	promote	angiogenesis	for	tissue	engineering,	J.	Control.	Release	150,	2011,	272–278.
Eppler	S.M.,	Combs	D.L.,	Henry	T.D.,	Lopez	J.J.,	Ellis	S.G.,	Yi	J.H.,	Annex	B.H.,	McCluskey	E.R.	and	Zioncheck	T.F.,	A	target-mediated	model	to	describe	the	pharmacokinetics	and	hemodynamic	effects	of	recombinant	human
vascular	endothelial	growth	factor	in	humans,	Clin.	Pharmacol.	Ther.	72,	2002,	20–32.
Faranesh	A.Z.,	Nastley	M.T.,	Perez	de	la	Cruz	C.,	Haller	M.F.,	Laquerriere	P.,	Leong	K.W.	and	McVeigh	E.R.,	In	vitro	release	of	vascular	endothelial	growth	factor	from	gadolinium-doped	biodegradable	microspheres,	Magn.
Reson.	Med.	51,	2004,	1265–1271.
Goerges	A.L.	and	Nugent	M.A.,	pH	regulates	vascular	endothelial	growth	factor	binding	to	fibronectin:	a	mechanism	for	control	of	extracellular	matrix	storage	and	release,	J.	Biol.	Chem.	279,	2004,	2307–2315.
He	Y.	and	Park	K.,	Effects	of	the	microparticle	shape	on	cellular	uptake,	Mol.	Pharm.	13,	2016,	2164–2171.
Henry	T.D.,	Rocha-Singh	K.,	Isner	J.M.,	Kereiakes	D.J.,	Giordano	F.J.,	Simons	M.,	Losordo	D.W.,	Hendel	R.C.,	Bonow	R.O.,	Eppler	S.M.,	Zioncheck	T.F.,	Holmgren	E.B.	and	McCluskey	E.R.,	Intracoronary	administration	of	recombinant
human	vascular	endothelial	growth	factor	to	patients	with	coronary	artery	disease,	Am.	Heart	J.	142,	2001,	872–880.
Hines	D.J.	and	Kaplan	D.L.,	Poly(lactic-co-glycolic)	acid-controlled-release	systems:	experimental	and	modeling	insights,	Crit.	Rev.	Ther.	Drug	Carrier	Syst.	30,	2013,	257–276.
Jiang	G.,	Woo	B.H.,	Kang	F.,	Singh	J.	and	DeLuca	P.P.,	Assessment	of	protein	release	kinetics,	stability	and	protein	polymer	interaction	of	lysozyme	encapsulated	poly(D,	L-lactide-co-glycolide)	microspheres,	J.	Control.
Release	79,	2002,	137–145.
Jiang	X.,	Xiong	Q.,	Xu	G.,	Lin	H.,	Fang	X.,	Cui	D.,	Xu	M.,	Chen	F.	and	Geng	H.,	VEGF-loaded	nanoparticle-modified	BAMAs	enhance	angiogenesis	and	inhibit	graft	shrinkage	in	tissue-engineered	bladder,	Ann.	Biomed.	Eng.	43
2015,	2577–2586.
Karvinen	H.,	Pasanen	E.,	Rissanen	T.T.,	Korpisalo	P.,	Vahakangas	E.,	Jazwa	A.,	Giacca	M.	and	Yla-Herttuala	S.,	Long-term	VEGF-A	expression	promotes	aberrant	angiogenesis	and	fibrosis	in	skeletal	muscle,	Gene	Ther.	18,	2011,
1166–1172.
Kirby	G.T.,	White	L.J.,	Steck	R.,	Berner	A.,	Bogoevski	K.,	Qutachi	O.,	Jones	B.,	Saifzadeh	S.,	Hutmacher	D.W.	and	Shakesheff	K.M.,	Microparticles	for	sustained	growth	factor	delivery	in	the	regeneration	of	critically-sized
segmental	tibial	bone	defects,	Materials	9,	2016,	259.
Kleinheinz	J.,	Jung	S.,	Wermker	K.,	Fischer	C.	and	Joos	U.,	Release	kinetics	of	VEGF165	from	a	collagen	matrix	and	structural	matrix	changes	in	a	circulation	model,	Head	Face	Med.	6,	2010,	17.
Kusumanto	Y.H.,	van	Weel	V.,	Mulder	N.H.,	Smit	A.J.,	van	den	Dungen	J.J.,	Hooymans	J.M.,	Sluiter	W.J.,	Tio	R.A.,	Quax	P.H.,	Gans	R.O.,	Dullaart	R.P.	and	Hospers	G.A.,	Treatment	with	intramuscular	vascular	endothelial	growth
factor	gene	compared	with	placebo	for	patients	with	diabetes	mellitus	and	critical	limb	ischemia:	a	double-blind	randomized	trial,	Hum.	Gene	Ther.	17,	2006,	683–691.
Langer	R.,	New	methods	of	drug	delivery,	Science	249,	1990,	1527–1533.
Lee	J.	and	Lee	K.Y.,	Local	and	sustained	vascular	endothelial	growth	factor	delivery	for	angiogenesis	using	an	injectable	system,	Pharm.	Res-Dord.	26,	2009,	1739–1744.
Morita	T.,	Horikiri	Y.,	Suzuki	T.	and	Yoshino	H.,	Applicability	of	various	amphiphilic	polymers	to	the	modification	of	protein	release	kinetics	from	biodegradable	reservoir-type	microspheres,	Eur.	J.	Pharm.	Biopharm.	51,
2001,	45–53.
Ozawa	C.R.,	Banfi	A.,	Glazer	N.L.,	Thurston	G.,	Springer	M.L.,	Kraft	P.E.,	McDonald	D.M.	and	Blau	H.M.,	Microenvironmental	VEGF	concentration,	not	total	dose,	determines	a	threshold	between	normal	and	aberrant
angiogenesis,	J.	Clin.	Invest.	113,	2004,	516–527.
Park	T.G.,	Degradation	of	poly(lactic-co-glycolic	acid)	microspheres:	effect	of	copolymer	composition,	Biomaterials	16,	1995,	1123–1130.
Porporato	P.E.,	Payen	V.L.,	De	Saedeleer	C.J.,	Preat	V.,	Thissen	J.P.,	Feron	O.	and	Sonveaux	P.,	Lactate	stimulates	angiogenesis	and	accelerates	the	healing	of	superficial	and	ischemic	wounds	in	mice,	Angiogenesis	15,	2012,
581–592.
Qodratnama	R.,	Serino	L.P.,	Cox	H.C.,	Qutachi	O.	and	White	L.J.,	Formulations	for	modulation	of	protein	release	from	large-size	PLGA	microparticles	for	tissue	engineering,	Mater	Sci	Eng	C	Mater	Biol	Appl	47,	2015,	230–236.
Qutachi	O.,	Vetsch	J.R.,	Gill	D.,	Cox	H.,	Scurr	D.J.,	Hofmann	S.,	Muller	R.,	Quirk	R.A.,	ShakeSheff	K.M.	and	Rahman	C.V.,	Injectable	and	porous	PLGA	microspheres	that	form	highly	porous	scaffolds	at	body	temperature,	Acta
Biomater.	10,	2014,	5090–5098.
Sacchi	V.,	Mittermayr	R.,	Hartinger	J.,	Martino	M.M.,	Lorentz	K.M.,	Wolbank	S.,	Hofmann	A.,	Largo	R.A.,	Marschall	J.S.,	Groppa	E.,	Gianni-Barrera	R.,	Ehrbar	M.,	Hubbell	J.A.,	Redl	H.	and	Banfi	A.,	Long-lasting	fibrin	matrices	ensure
stable	and	functional	angiogenesis	by	highly	tunable,	sustained	delivery	of	recombinant	VEGF164,	Proc.	Natl.	Acad.	Sci.	USA	111,	2014,	6952–6957.
Sah	H.K.,	A	new	strategy	to	determine	the	actual	protein	content	of	poly(lactide-co-glycolide)	microspheres,	J.	Pharm.	Sci.	86,	1997,	1315–1318.
Sandor	M.,	Enscore	D.,	Weston	P.	and	Mathiowitz	E.,	Effect	of	protein	molecular	weight	on	release	from	micron-sized	PLGA	microspheres,	J.	Control.	Release	76,	2001,	297–311.
Silva	E.A.	and	Mooney	D.J.,	Spatiotemporal	control	of	vascular	endothelial	growth	factor	delivery	from	injectable	hydrogels	enhances	angiogenesis,	J.	Thromb.	Haemost.	5,	2007,	590–598.
Takeshita	S.,	Zheng	L.P.,	Brogi	E.,	Kearney	M.,	Pu	L.Q.,	Bunting	S.,	Ferrara	N.,	Symes	J.F.	and	Isner	J.M.,	Therapeutic	angiogenesis.	A	single	intraarterial	bolus	of	vascular	endothelial	growth	factor	augments	revascularization
in	a	rabbit	ischemic	hind	limb	model,	J.	Clin.	Invest.	93,	1994,	662–670.
Tayalia	P.	and	Mooney	D.J.,	Controlled	growth	factor	delivery	for	tissue	engineering,	Adv.	Mater.	21,	2009,	3269–3285.
Tenna	A.S.,	Watson	A.	and	Stansby	G.,	Revascularization	for	critical	limb	ischemia	in	diabetes:	surgery	or	angioplasty?,	Angiology	65,	2014,	272–273.
van	de	Weert	M.,	Hennink	W.E.	and	Jiskoot	W.,	Protein	instability	in	poly(lactic-co-glycolic	acid)	microparticles,	Pharm.	Res.	17,	2000,	1159–1167.
White	L.J.,	Kirby	G.T.,	Cox	H.C.,	Qodratnama	R.,	Qutachi	O.,	Rose	F.R.	and	Shakesheff	K.M.,	Accelerating	protein	release	from	microparticles	for	regenerative	medicine	applications,	Mater	Sci.	Eng.	C	Mater.	Biol.	Appl.	33,	2013
2578–2583.
Yoon	Y.S.,	Johnson	I.A.,	Park	J.S.,	Diaz	L.	and	Losordo	D.W.,	Therapeutic	myocardial	angiogenesis	with	vascular	endothelial	growth	factors,	Mol.	Cell.	Biochem.	264,	2004,	63–74.
Queries	and	Answers
Query:	Your	article	is	registered	as	a	regular	item	and	is	being	processed	for	inclusion	in	a	regular	issue	of	the	journal.	If	this	is	NOT	correct	and	your	article	belongs	to	a	Special	Issue/Collection	please
contact	j.paulinj@elsevier.com	immediately	prior	to	returning	your	corrections.
Answer:	Yes
Query:	The	author	names	have	been	tagged	as	given	names	and	surnames	(surnames	are	highlighted	in	teal	color).	Please	confirm	if	they	have	been	identified	correctly.
Answer:	Yes
Query:	Correctly	acknowledging	the	primary	funders	and	grant	IDs	of	your	research	is	important	to	ensure	compliance	with	funder	policies.	We	could	not	find	any	acknowledgement	of	funding	sources
in	your	text.	Is	this	correct?	/
Answer:	Yes
Yu	Y.,	Chen	J.,	Chen	R.,	Cao	L.,	Tang	W.,	Lin	D.,	Wang	J.	and	Liu	C.,	Enhancement	of	VEGF-mediated	angiogenesis	by	2-N,6-O-sulfated	chitosan-coated	hierarchical	PLGA	scaffolds,	ACS	Appl.	Mater.	Interfaces	7,	2015,
9982–9990.
Yue	X.	and	Tomanek	R.J.,	Effects	of	VEGF(165)	and	VEGF(121)	on	vasculogenesis	and	angiogenesis	in	cultured	embryonic	quail	hearts,	Am.	J.	Physiol.	Heart	Circ.	Physiol.	280,	2001,	H2240–2247.
Graphical	abstract
